The post marketing observational program "Sovet" has been launched in 2011. Sixty-nine patients with relapsing-remitting multiple sclerosis (MS) treated with natalizumab (NZ), a second generation DMD, have been examined. NZ infusions were carried out during 1h every 4 weeks for 12 months. After treatment, there were a significant reduction in the frequency of relapses from 2.22±0.98 to 0.18±0.42 per year and a trend towards the decrease in EDSS scores from 3.69±1.00 to 3.37±1.17. Adverse effects were noted in 11 patients, with each patient having no more than one side-effect. One patient discontinued treatment due to a generalized allergic reaction. These findings are in line with literature results on the positive effect of NZ on the course and symptoms of MS. It has been concluded, that the strict selection of patients and their correct management during the treatment with NZ may provide the positive balance between advantages and potential risks.